Information Provided By: 
Fly News Breaks for November 10, 2015
JAZZ
Nov 10, 2015 | 06:53 EDT
Citi analyst Liav Abraham cut his priced target for Jazz Pharmaceuticals to $164 but keeps a Buy rating on the name following the company's Q3 results. The light Xyrem sales were the result of disruption at the central pharmacy following the implementation of the recently agreed upon REMS program for the product with FDA, Abraham tells investors in a post-earnings research note. He found management commentary regarding the "very strong" volume growth for Xyrem prior to the disruptions as encouraging.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
